You have 9 free searches left this month | to do more

degarelix

Degarelix is a drug used to treat Prostate Cancer, Prostate Adenocarcinoma, and Prostatic Neoplasms. Degarelix is being actively studied in 25 studies and prior, has been studied in 46.

Top SponsorsTop SitesTop Investigators
Ferring PharmaceuticalsSouth Florida Medical ResearchMatthew Dallos
Memorial Sloan Kettering Cancer CenterAdvanced Urology Medical CenterRobert J Amato
M.D. Anderson Cancer CenterSouth Orange County Medical Research CenterAlessandro Antonelli
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Recruiting
  • Prostate Cancer
  • BMS-986218 and Degarelix
  • Degarelix
  • New York, New York
    Columbia University Irving Medical Center
2021-10-27
Oct 27, 2021
M
Active, not recruiting
  • Metastatic Prostatic Adenocarcinoma
  • Charleston, South Carolina
    Medical University of South Carolina
2021-04-29
Apr 29, 2021
U
Recruiting
  • Prostate Cancer
  • +3 more
  • Leuven, Vlaams-brabant, Belgium
    University Hospitals Leuven
2020-12-23
Dec 23, 2020
A
Recruiting
  • Pregnancy, Ovarian
  • Degarelix
  • Thessaloníki, Greece
    Assisting Nature
2020-10-06
Oct 6, 2020
U
Completed
  • Stage III Prostate Adenocarcinoma AJCC v7
  • +3 more
  • Abiraterone Acetate
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-12-15
Dec 15, 2021
U
Not yet recruiting
  • Prostate Cancer
  • Toronto, Ontario, Canada
    UHN Princess Margaret Hospital
2021-04-16
Apr 16, 2021
O
Terminated
  • Prostatic Neoplasms
  • Degarelix
  • London, Ontario, Canada
  • +2 more
2020-05-05
May 5, 2020
B
Completed
  • Prostate Cancer
  • Degarelix
  • Abbottsford, British Columbia, Canada
  • +2 more
2020-01-23
Jan 23, 2020
U
Active, not recruiting
  • Prostate Cancer
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2021-12-27
Dec 27, 2021
M
Active, not recruiting
  • Leukemia
  • +3 more
  • Palifermin
  • +6 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-04-14
Apr 14, 2021
A
Recruiting
  • Bladder Cancer
  • +2 more
  • Degarelix
  • Aarhus, Denmark
    Aarhus University Hospital
2021-07-27
Jul 27, 2021
B
Active, not recruiting
  • Prostate Cancer
  • Boston, Massachusetts
    Brigham and Women's Hospital
2021-05-18
May 18, 2021
R
Not yet recruiting
  • Hormone Sensitive Prostate Cancer
  • +2 more
  • Degarelix
  • GnRH agonist
  • Petah Tikva, Israel
    Rabin Medical Center - Beilinson Hospital
2019-11-27
Nov 27, 2019
M
Recruiting
  • Prostate Cancer
  • Adenocarcinoma of the Prostate
  • New York, New York
  • +2 more
2021-01-12
Jan 12, 2021
S
Completed
  • Stage IV Prostate Cancer
  • Cryosurgery
  • +3 more
  • Baltimore, Maryland
    Johns Hopkins University/Sidney Kimmel Cancer Center
2021-11-11
Nov 11, 2021
U
Recruiting
  • Prostate Cancer
  • Degarelix
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2021-12-27
Dec 27, 2021
W
Recruiting
  • Prostatic Neoplasms
  • Cheongju, Korea, Republic of
  • +9 more
2021-07-28
Jul 28, 2021
F
Completed
  • Advanced Prostate Cancer
  • Degarelix
  • LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
  • Rottweil, Germany
    Investigational site (there may be other sites in this country)
2019-07-01
Jul 1, 2019
C
Completed
  • Prostate Cancer
  • Cambridge, Cambridgeshire, United Kingdom
    Addenbrooke's Hospital, Cambridge University Hospitals Foundatio
2019-08-28
Aug 28, 2019
J
Active, not recruiting
  • Prostate Cancer
  • degarelix
  • +3 more
  • Los Angeles, California
    University of California, Los Angeles
2021-08-03
Aug 3, 2021
S
Suspended
  • Prostate Adenocarcinoma
  • +4 more
  • Internal Radiation Therapy
  • +7 more
  • Stanford, California
    Stanford University, School of Medicine
2021-07-28
Jul 28, 2021
I
Completed
  • Breast Cancer Invasive Nos
  • Bologna, Italy
  • +6 more
2019-05-28
May 28, 2019
U
Completed
  • Prostate Cancer
  • Degarelix
  • Planegg, Bavaria, Germany
    UCM GmbH
2020-04-09
Apr 9, 2020